ABSTRACT
La presente investigación tuvo como objetivo determinar la relación entre los tipos de liderazgo y satisfacción laboral del personal del hospital Alberto Hurtado Abadia ESSALUD - La Oroya, 2018. El método que se utilizó fue el descriptivo, el tipo sustantivo descriptivo, el nivel descriptivo, el diseño fue descriptivo correlacional. La muestra estuvo constituida por 202 trabajadores del hospital mencionado, la recolección de datos se realizó con la "Escala de Liderazgo Organizacional - ELO" y la "Escala de Satisfacción Laboral (SL-SPC)". Para el procesamiento de datos se utilizó el programa SPSS versión 24, donde se realizaron la comprobación de hipótesis utilizando el coeficiente de Chi-cuadrado de Pearson se encontró que existe relación significativa entre las variables medidas, cuyo valor de significancia fue de 0,000 < 0,05. Se concluye entonces que los estilos de liderazgo y la satisfacción laboral se relacionan y se desarrollan simultáneamente, sin embargo, dependerá del tipo de liderazgo y las actitudes y decisiones que tome para generar la satisfacción de sus subordinados y la de ellos mismos. Palabras Claves: Tipos de liderazgo y Satisfacción Laboral.
Subject(s)
Humans , Job Satisfaction , Leadership , Health Personnel , Health FacilitiesABSTRACT
Fundamento y objetivo: La hemoglobinuria paroxística nocturna es una enfermedad clonal adquirida caracterizada por hemólisis mediada por complemento, insuficiencia medular y enfermedad tromboembólica. El eculizumab es un anticuerpo monoclonal dirigido contra la fracción C5 del complemento, que bloquea la formación del componente citolítico de este.Pacientes y método: Se estudian 25 pacientes en tratamiento con eculizumab en España. El análisis estadístico se realiza con el software SPSS v15.0. Resultados:Con una mediana de seguimiento de 14 meses (extremos 3-46), el eculizumab ha conseguido independencia transfusional en 58% de los pacientes y disminución del 60% de los requerimientos transfusionales en el resto de los pacientes, desaparición de la astenia en 96% de los casos y de los síntomas de distonía de músculo liso en la totalidad. Sólo un paciente ha presentado infección grave relacionada con el tratamiento.Conclusiones: El tratamiento con eculizumab es eficaz en el control de la hemólisis, con gran mejoría clínica. El fármaco es seguro y bien tolerado, sin efectos secundarios significativos, salvo el riesgo de infección meningocócica. En pacientes con respuesta subóptima a eculizumab es preciso valorar el grado de insuficiencia medular y la posibilidad de hemólisis extravascular (AU)
Background and objectives: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal disease characterized by complement-mediated hemolysis, bone marrow failure and thrombosis. Eculizumab is a humanized monoclonal antibody that blocks the cytolytic component of the complement system by binding to complement C5. Material and Methods: We report the results of eculizumab treatment in 25 PNH patients from different centers in Spain. Statistical analysis was perfomed with a SPSS v15.0 software.Results: Fifty-eight per cent of the patients achieved transfusional independence after a median of 14 months. Transfusion requirements were reduced in 60% of the remaining cases. Fatigue resolved in 96% of the patients and smooth muscle dystony-related symptoms in all cases. A single case of treatment-related infection was observed. Conclusions: Eculizumab controls effectively hemolysis and greatly improves clinical symptoms. The drug is safe and well tolerated, without significant adverse effects except meningococcal infection. Patients with suboptimal response to treatment must be assessed for bone marrow insufficiency and extravascular haemolysis (AU)
Subject(s)
Humans , Hemoglobinuria, Paroxysmal/drug therapy , Antibodies, Monoclonal/therapeutic use , Hemolysis , Blood Transfusion , Risk FactorsABSTRACT
BACKGROUND AND OBJECTIVES: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal disease characterized by complement-mediated hemolysis, bone marrow failure and thrombosis. Eculizumab is a humanized monoclonal antibody that blocks the cytolytic component of the complement system by binding to complement C5. MATERIAL AND METHODS: We report the results of eculizumab treatment in 25 PNH patients from different centers in Spain. Statistical analysis was perfomed with a SPSS v15.0 software. RESULTS: Fifty-eight per cent of the patients achieved transfusional independence after a median of 14 months. Transfusion requirements were reduced in 60% of the remaining cases. Fatigue resolved in 96% of the patients and smooth muscle dystony-related symptoms in all cases. A single case of treatment-related infection was observed. CONCLUSIONS: Eculizumab controls effectively hemolysis and greatly improves clinical symptoms. The drug is safe and well tolerated, without significant adverse effects except meningococcal infection. Patients with suboptimal response to treatment must be assessed for bone marrow insufficiency and extravascular haemolysis.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Hemoglobinuria, Paroxysmal/drug therapy , Adolescent , Adult , Aged , Antibodies, Monoclonal, Humanized , Child , Female , Humans , Male , Middle Aged , Spain , Young AdultABSTRACT
Banana starch was isolated to obtain maltodextrin by enzymatic hydrolysis with a heat-stable alpha-amylase. The maltodextrin obtained had a dextrose equivalent (DE) between 7-11 and showed suitable chemical characteristics for food application. Additionally, banana maltodextrin had a greater white color value and total color difference (delta E) than a sample of commercial maltodextrin. Further saccharification of the maltodextrins was carried out with amyloglucosidase and pullulanase at 60 degrees C during 24 h obtaining a glucose syrup. Chemical characteristics of banana glucose syrup were compared with those of a commercial syrup obtaining similar results. Nevertheless, the color of banana glucose syrup was clearer than the one of a sample of commercial syrup. However, it showed lower color stability than the commercial sample, i.e., the color of banana glucose syrup changed as a function of storage time. Banana starch may be used to obtain maltodextrins and glucose syrups with similar chemical characteristics of those obtained from maize starch. Particularly, the color of banana maltodextrin is adequate for its use in food products.
Subject(s)
Glucose/chemical synthesis , Musa , Polysaccharides/chemical synthesis , Starch/metabolism , HydrolysisABSTRACT
ABSTRACT: Banana starch was isolated to obtain maltodextrin by enzymatic hydrolysis with a heat-stable _-amylase. The maltodextrin obtained had a dextrose equivalent (DE) between 7-11 and showed suitable chemical characteristics for food application. Additionally, banana maltodextrin had a greater white color value and total color difference (_E) than a sample of commercial maltodextrin. Further saccharification of the maltodextrins was carried out with amyloglucosidase and pullulanase at 60 ÆC during 24 h obtaining a glucose syrup. Chemical characteristics of banana glucose syrup were compared with those of a commercial syrup obtaining similar results. Nevertheless, the color of banana glucose syrup was clearer than the one of a sample of commercial syrup. However, it showed lower color stability than the commercial sample, i.e., the color of banana glucose syrup changed as a function of storage time. Banana starch may be used to obtain maltodextrins and glucose syrups with similar chemical characteristics of those obtained from maize starch. Particularly, the color of banana maltodextrin is adequate for its use in food products.
